Objectives: GH deficiency (GHD) and small for gestational age (SGA) status are associated with cardiovascular risks. We therefore investigated antiatherogenic effects of GH.
Methods: Subfractions of LDL and HDL, lipoprotein-associated phospholipase A2 (Lp-PLA2), and high-sensitivity C-reactive protein (hsCRP) were measured at baseline, after 8 and 52 weeks of GH treatment in 51 short children born SGA (n=33) or with GHD (n=18).
Results: For the overall group, we found post-treatment reductions of LDL cholesterol (P=0.016), small-dense LDL cholesterol (P<0.001), Lp-PLA2 (P<0.001), and hsCRP (P=0.005), but increases of HDL2a cholesterol (P=0.025). SGA children showed reductions of small-dense LDL cholesterol (P=0.02), Lp-PLA2 (P=0.002), hsCRP (P=0.037) and increases of HDL2a cholesterol (P=0.004). GH deficient children had non-significant decreases of small-dense LDL cholesterol, Lp-PLA2, hsCRP and increases of HDL2a cholesterol.
Conclusions: Children with GHD or born SGA may benefit from GH treatment by growth acceleration and simultaneous reduction of their latent cardiovascular long-term risk.
01 - 03 Oct 2015
European Society for Paediatric Endocrinology